Ascentage Pharma Group International (NASDAQ:AAPG) Raised to “Strong-Buy” at China Intl Cap

Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by research analysts at China Intl Cap to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts have also issued reports on the stock. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Thursday, March 26th. Two investment analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Trading Down 1.9%

Shares of NASDAQ AAPG opened at $26.90 on Monday. The firm has a fifty day moving average of $24.01 and a 200 day moving average of $29.08. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a one year low of $17.56 and a one year high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the third quarter valued at about $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International in the third quarter valued at about $204,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.